{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:00:17Z","timestamp":1795111217314,"version":"4.10.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 AI148378-01S1"],"award-info":[{"award-number":["RO1 AI148378-01S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["2166"],"award-info":[{"award-number":["2166"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100000097","name":"U.S. Department of Health & Human Services | NIH | National Center for Research Resources","doi-asserted-by":"publisher","award":["P51 OD011132"],"award-info":[{"award-number":["P51 OD011132"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is a great need for the development of vaccines that induce potent and long-lasting protective immunity against SARS-CoV-2. Multimeric display of the antigen combined with potent adjuvant can enhance the potency and longevity of the antibody response. The receptor binding domain (RBD) of the spike protein is a primary target of neutralizing antibodies. Here, we developed a trimeric form of the RBD and show that it induces a potent neutralizing antibody response against live virus with diverse effector functions and provides protection against SARS-CoV-2 challenge in mice and rhesus macaques. The trimeric form induces higher neutralizing antibody titer compared to monomer with as low as 1\u03bcg antigen dose. In mice, adjuvanting the protein with a TLR7\/8 agonist formulation alum-3M-052 induces 100-fold higher neutralizing antibody titer and superior protection from infection compared to alum. SARS-CoV-2 infection causes significant loss of innate cells and pathology in the lung, and vaccination protects from changes in innate cells and lung pathology. These results demonstrate RBD trimer protein as a suitable candidate for vaccine against SARS-CoV-2.<\/jats:p>","DOI":"10.1038\/s41467-021-23942-y","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T06:05:00Z","timestamp":1623391500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung"],"prefix":"10.1038","volume":"12","author":[{"given":"Nanda Kishore","family":"Routhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayanaiah","family":"Cheedarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Satish","family":"Bollimpelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailaja","family":"Gangadhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-7839","authenticated-orcid":false,"given":"Venkata Viswanadh","family":"Edara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusmita","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalnesh","family":"Shiferaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany M.","family":"Styles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-6961","authenticated-orcid":false,"given":"Katharine","family":"Floyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2307-3379","authenticated-orcid":false,"given":"Stephanie","family":"Fischinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-0232","authenticated-orcid":false,"given":"Caroline","family":"Atyeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9306-2264","authenticated-orcid":false,"given":"Sally A.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Gumber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Kirejczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Kenneth H.","family":"Dinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-1616","authenticated-orcid":false,"given":"Pei-Yong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8803-7606","authenticated-orcid":false,"given":"Vineet D.","family":"Menachery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-9215","authenticated-orcid":false,"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Vanderford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-8002","authenticated-orcid":false,"given":"Lisa","family":"Gralinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul S.","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6309-6797","authenticated-orcid":false,"given":"Rama Rao","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"23942_CR1","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med."},{"key":"23942_CR2","doi-asserted-by":"publisher","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594\u2013599, https:\/\/doi.org\/10.1038\/s41586-020-2814-7 (2020).","DOI":"10.1038\/s41586-020-2814-7"},{"key":"23942_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","volume":"15","author":"MD Shin","year":"2020","unstructured":"Shin, M. D. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646\u2013655 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"23942_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/22221751.2019.1624482","volume":"8","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Antibodies and vaccines against Middle East respiratory syndrome coronavirus. Emerg. Microbes Infect. 8, 841\u2013856 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"23942_CR5","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","volume":"10","author":"CY Yong","year":"2019","unstructured":"Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L. & Tan, W. S. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. Front. Microbiol 10, 1781 (2019).","journal-title":"Front. Microbiol"},{"key":"23942_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1128\/CMR.00102-14","volume":"28","author":"JF Chan","year":"2015","unstructured":"Chan, J. F. et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28, 465\u2013522 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"23942_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.aad1283","volume":"351","author":"BL Haagmans","year":"2016","unstructured":"Haagmans, B. L. et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351, 77\u201381 (2016).","journal-title":"Science"},{"key":"23942_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/postgradmedj-2020-138386","volume":"97","author":"MT Adil","year":"2021","unstructured":"Adil, M. T. et al. SARS-CoV-2 and the pandemic of COVID-19. Postgrad. Med. J. 97, 110\u2013116 (2021).","journal-title":"Postgrad. Med. J."},{"key":"23942_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","volume":"21","author":"L Dai","year":"2021","unstructured":"Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73\u201382 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"23942_CR10","doi-asserted-by":"publisher","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263, https:\/\/doi.org\/10.1126\/science.abb2507 (2020).","DOI":"10.1126\/science.abb2507"},{"key":"23942_CR11","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/jmv.26212","volume":"92","author":"AM Baig","year":"2020","unstructured":"Baig, A. M., Khaleeq, A. & Syeda, H. Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis. J. Med. Virol. 92, 2792\u20132803 (2020).","journal-title":"J. Med. Virol."},{"key":"23942_CR12","doi-asserted-by":"publisher","unstructured":"Keech, C. et al. Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320-2332, https:\/\/doi.org\/10.1056\/NEJMoa2026920 (2020).","DOI":"10.1056\/NEJMoa2026920"},{"key":"23942_CR13","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.1016\/j.vaccine.2020.10.064","volume":"38","author":"M Guebre-Xabier","year":"2020","unstructured":"Guebre-Xabier, M. et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine 38, 7892\u20137896 (2020).","journal-title":"Vaccine"},{"key":"23942_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20653-8","volume":"12","author":"JH Tian","year":"2021","unstructured":"Tian, J. H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372 (2021).","journal-title":"Nat. Commun."},{"key":"23942_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","volume":"586","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572\u2013577 (2020).","journal-title":"Nature"},{"key":"23942_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","volume":"53","author":"Y Kato","year":"2020","unstructured":"Kato, Y. et al. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 53, 548\u2013563 e548 (2020).","journal-title":"Immunity"},{"key":"23942_CR17","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/infdis\/jiy360","volume":"218","author":"K Haltaufderhyde","year":"2018","unstructured":"Haltaufderhyde, K. et al. Activation of peripheral T follicular helper cells during acute dengue virus infection. J. Infect. Dis. 218, 1675\u20131685 (2018).","journal-title":"J. Infect. Dis."},{"key":"23942_CR18","doi-asserted-by":"publisher","first-page":"e1005777","DOI":"10.1371\/journal.ppat.1005777","volume":"12","author":"R Muir","year":"2016","unstructured":"Muir, R. et al. Altered memory circulating T follicular Helper-B cell interaction in early acute HIV infection. PLoS Pathog. 12, e1005777 (2016).","journal-title":"PLoS Pathog."},{"key":"23942_CR19","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367\u20131382.e1317 (2020).","journal-title":"Cell"},{"key":"23942_CR20","doi-asserted-by":"publisher","unstructured":"He, L. et al. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. Sci Adv 7 https:\/\/doi.org\/10.1126\/sciadv.abf1591 (2021).","DOI":"10.1126\/sciadv.abf1591"},{"key":"23942_CR21","doi-asserted-by":"publisher","unstructured":"Kang, Y. F. et al. Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates. ACS Nano 15, 2738\u20132752 https:\/\/doi.org\/10.1021\/acsnano.0c08379 (2021).","DOI":"10.1021\/acsnano.0c08379"},{"key":"23942_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20654-7","volume":"12","author":"TK Tan","year":"2021","unstructured":"Tan, T. K. et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat. Commun. 12, 542 (2021).","journal-title":"Nat. Commun."},{"key":"23942_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492\u2013503 (2010).","journal-title":"Immunity"},{"key":"23942_CR24","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","volume":"29","author":"D Smirnov","year":"2011","unstructured":"Smirnov, D., Schmidt, J. J., Capecchi, J. T. & Wightman, P. D. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29, 5434\u20135442 (2011).","journal-title":"Vaccine"},{"key":"23942_CR25","doi-asserted-by":"publisher","unstructured":"Kasturi, S. P. et al. 3M-052, a synthetic TLR-7\/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Sci Immunol 5 https:\/\/doi.org\/10.1126\/sciimmunol.abb1025 (2020).","DOI":"10.1126\/sciimmunol.abb1025"},{"key":"23942_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41591-020-0858-8","volume":"26","author":"PS Arunachalam","year":"2020","unstructured":"Arunachalam, P. S. et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat. Med. 26, 932\u2013940 (2020).","journal-title":"Nat. Med."},{"key":"23942_CR27","doi-asserted-by":"publisher","unstructured":"Burton, S. et al. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants. J Virol 93 https:\/\/doi.org\/10.1128\/JVI.01846-18 (2019).","DOI":"10.1128\/JVI.01846-18"},{"key":"23942_CR28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","volume":"183","author":"SR Leist","year":"2020","unstructured":"Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070\u20131085 e1012 (2020).","journal-title":"Cell"},{"key":"23942_CR29","doi-asserted-by":"publisher","unstructured":"Kasturi, S. P. et al. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5alpha Restrictive Macaques. J Virol 91 https:\/\/doi.org\/10.1128\/JVI.01844-16 (2017).","DOI":"10.1128\/JVI.01844-16"},{"key":"23942_CR30","doi-asserted-by":"crossref","unstructured":"Arunachalam, P. S. et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat. Med. (2020).","DOI":"10.1038\/s41591-020-0858-8"},{"key":"23942_CR31","first-page":"248","volume":"53","author":"A Sariol","year":"2020","unstructured":"Sariol, A. & Perlman, S. Lessons for COVID-19. Immun. Other Coronavirus Infect. Immun. 53, 248\u2013263 (2020).","journal-title":"Immun. Other Coronavirus Infect. Immun."},{"key":"23942_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1056\/NEJMc2032195","volume":"384","author":"AT Widge","year":"2021","unstructured":"Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80\u201382 (2021).","journal-title":"N. Engl. J. Med."},{"key":"23942_CR33","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880 (2021).","journal-title":"Cell"},{"key":"23942_CR34","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012.e1019 (2020).","journal-title":"Cell"},{"key":"23942_CR35","doi-asserted-by":"publisher","unstructured":"van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578\u2013582 https:\/\/doi.org\/10.1038\/s41586-020-2608-y (2020).","DOI":"10.1038\/s41586-020-2608-y"},{"key":"23942_CR36","doi-asserted-by":"publisher","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 https:\/\/doi.org\/10.1038\/s41586-021-03275-y (2021).","DOI":"10.1038\/s41586-021-03275-y"},{"key":"23942_CR37","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722\u2013733 e711 (2020).","journal-title":"Cell"},{"key":"23942_CR38","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367\u20131382 e1317 (2020).","journal-title":"Cell"},{"key":"23942_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21665-8","volume":"12","author":"HX Tan","year":"2021","unstructured":"Tan, H. X. et al. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nat. Commun. 12, 1403 (2021).","journal-title":"Nat. Commun."},{"key":"23942_CR40","doi-asserted-by":"publisher","unstructured":"Malladi, S. K. et al. Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. J Biol Chem, https:\/\/doi.org\/10.1074\/jbc.RA120.016284 (2020).","DOI":"10.1074\/jbc.RA120.016284"},{"key":"23942_CR41","doi-asserted-by":"publisher","first-page":"129893","DOI":"10.1016\/j.bbagen.2021.129893","volume":"1865","author":"WH Chen","year":"2021","unstructured":"Chen, W. H. et al. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim. Biophys. Acta 1865, 129893 (2021).","journal-title":"Biochim. Biophys. Acta"},{"key":"23942_CR42","doi-asserted-by":"publisher","unstructured":"Brouwer, P. J. M. et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell184, 1188-1200 e1119 https:\/\/doi.org\/10.1016\/j.cell.2021.01.035 (2021).","DOI":"10.1016\/j.cell.2021.01.035"},{"key":"23942_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19967-4","volume":"11","author":"MD Fahlberg","year":"2020","unstructured":"Fahlberg, M. D. et al. Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates. Nat. Commun. 11, 6078 (2020).","journal-title":"Nat. Commun."},{"key":"23942_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41564-020-00841-4","volume":"6","author":"DK Singh","year":"2021","unstructured":"Singh, D. K. et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat. Microbiol 6, 73\u201386 (2021).","journal-title":"Nat. Microbiol"},{"key":"23942_CR45","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","volume":"26","author":"M Liao","year":"2020","unstructured":"Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med 26, 842\u2013844 (2020).","journal-title":"Nat. Med"},{"key":"23942_CR46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848 e843 (2020).","journal-title":"Cell Host Microbe"},{"key":"23942_CR47","doi-asserted-by":"publisher","unstructured":"Routhu, N. K. et al. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Immunity 54, 542\u2013556 e549, https:\/\/doi.org\/10.1016\/j.immuni.2021.02.001 (2021).","DOI":"10.1016\/j.immuni.2021.02.001"},{"key":"23942_CR48","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.4049\/jimmunol.1501243","volume":"195","author":"V Chamcha","year":"2015","unstructured":"Chamcha, V., Jones, A., Quigley, B. R., Scott, J. R. & Amara, R. R. Oral immunization with a recombinant lactococcus lactis-expressing HIV-1 antigen on Group A Streptococcus pilus induces strong mucosal immunity in the gut. J. Immunol. 195, 5025\u20135034 (2015).","journal-title":"J. Immunol."},{"key":"23942_CR49","doi-asserted-by":"publisher","first-page":"e0006862","DOI":"10.1371\/journal.pntd.0006862","volume":"12","author":"LC Katzelnick","year":"2018","unstructured":"Katzelnick, L. C. et al. Viridot: an automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. PLoS Negl. Trop. Dis. 12, e0006862 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"23942_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jim.2017.01.010","volume":"443","author":"EP Brown","year":"2017","unstructured":"Brown, E. P. et al. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J. Immunol. Methods 443, 33\u201344 (2017).","journal-title":"J. Immunol. Methods"},{"key":"23942_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","volume":"366","author":"ME Ackerman","year":"2011","unstructured":"Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8\u201319 (2011).","journal-title":"J. Immunol. Methods"},{"key":"23942_CR52","doi-asserted-by":"publisher","first-page":"112630","DOI":"10.1016\/j.jim.2019.07.002","volume":"473","author":"S Fischinger","year":"2019","unstructured":"Fischinger, S. et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods 473, 112630 (2019).","journal-title":"J. Immunol. Methods"},{"key":"23942_CR53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jim.2019.05.006","volume":"471","author":"CB Karsten","year":"2019","unstructured":"Karsten, C. B. et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. J. Immunol. Methods 471, 46\u201356 (2019).","journal-title":"J. Immunol. Methods"},{"key":"23942_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.1058915","volume":"292","author":"RR Amara","year":"2001","unstructured":"Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA\/MVA vaccine. Science 292, 69\u201374 (2001).","journal-title":"Science"},{"key":"23942_CR55","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R Wolfel","year":"2020","unstructured":"Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465\u2013469 (2020).","journal-title":"Nature"},{"key":"23942_CR56","doi-asserted-by":"crossref","unstructured":"Waggoner, J. J. et al. Triplex real-time RT-PCR for severe acute respiratory syndrome coronavirus 2. Emerg. Infect. Dis. 26, 1633\u20131635 (2020).","DOI":"10.3201\/eid2607.201285"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23942-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T08:04:19Z","timestamp":1669968259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23942-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["23942"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-23942-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"assertion":[{"value":"23 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.R.A., N.C. and N.K.R are co-inventors of RBD trimer vaccine technology. Emory university filed a patent on this technology. C.B.F is an\u00a0inventor on a patent application\u00a0of the 3M-052-Alum formulation.\u00a0All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Mice and rhesus macaques were housed at the Yerkes National Primate Research Center and animal experiments were approved by the Emory University Institutional Animal Care and Use Committee (IACUC) using protocols PROTO201700014 and PROTO202000057. All animal experiments were carried out in accordance to USDA regulations and recommendations derived from the Guide for the Care and Use of Laboratory Animals. Mice were shipped to the University of North Carolina (UNC) at Chapel Hill and performed SARS-CoV-2 (MA10) challenge experiments using IACUC protocol 20-114.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"3587"}}